Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277221 | 0.92 | KIT (0.39) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL10277219 | 0.92 | KIT (0.39) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL10277070 | 0.87 | POLB (0.41) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL10308715 | 0.87 | POLB (0.41) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL9956747 | 0.86 | POLB (0.42) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL9956751 | 0.86 | POLB (0.42) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL10276929 | 0.86 | EPHX2 (0.42) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL10276935 | 0.86 | EPHX2 (0.42) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL9956305 | 0.86 | POLB (0.42) | POLBKDM4EALDH1A1LMNAGLA | |
| SCHEMBL9956301 | 0.86 | POLB (0.42) | POLBKDM4EALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | POLB 958/4885KDM4E 2693/4885ALDH1A1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.